M. Sinead O'Mahony
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
M. Sinead O'Mahony has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
John A. Steward
Welsh Cancer Intelligence and Surveillance Unit Cardiff UK
4 shared publicationsShu F. Ho
University Department of Geriatric Medicine, Llandough Hospital, Cardiff, UK
4 shared publicationsMaurice Buchalter
University Hospital of Wales Cardiff UK
3 shared publicationsMichael L. Burr
Department of Epidemiology, Statistics and Public Health Medicine University of Wales College of Medicine Cardiff UK
3 shared publicationsPatricia Breay
2 shared publicationsSyamasis Bandyopadhyay
University Department of Geriatric Medicine, Llandough Hospital, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX, UK
2 shared publications
Latest Publications
- 1 January 2008
- Published by Springer Nature in Drugs & Aging
- Vol. 25 (5) , 415-443
Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People
Asthma and chronic obstructive pulmonary disease (COPD) are common disorders that are associated with increasing morbidity and mortality in older people. Bronchodilators are used widely in patients with these conditions, but even when used in inhaled form can have systemic as well as local effects. Older people experience more adverse drug effects because of pharmacodynamic and pharmacokinetic changes and particularly drug-drug and drug-disease interactions. Cardiovascular disease is common in older people and β-adrenoceptor agonists (β-agonists) have inotropic and chronotropic effects that can increase arrhythmias and cardiomyopathy. They can also worsen or induce myocardial ischaemia and cause electrolyte disturbances that contribute to arrhythmias. Tremor is a well known distressing adverse effect of β-agonist administration. Long-term β-agonist use can be associated with tolerance, poor disease control, sudden life-threatening exacerbations and asthma-related deaths. Functional β2-adrenoceptors are present in osteoblasts, and chronic use of β-agonists has been implicated in osteoporosis. Inhaled anticholinergics are usually well tolerated but may cause dry mouth, which can be troublesome in older people. Pupillary dilatation, blurred vision and acute glaucoma can occur from escape of droplets from loosely fitting nebulizer masks. Although ECG changes have not been seen in randomized controlled trials of long-acting inhaled anticholinergics, supraventricular tachycardias have been observed in a 5-year randomized controlled trial of ipratropium bromide. Paradoxical bronchoconstriction can occur with inhaled anticholinergics as well as with β-agonists, but tolerance has not been reported with anticholinergics. Anticholinergic drugs also cause central effects, most notably impairment of cognitive function, and these effects have been noted with inhaled agents. Use of theophylline is limited by its adverse effects, which range from commonly occurring gastrointestinal symptoms to palpitations, arrhythmias and reports of myocardial infarction. Seizures have been reported, but are rare. Theophylline is metabolized primarily by the liver, and commonly interacts with other medications. Its concentration in plasma should be monitored closely, especially in older people. Although many clinical trials have been conducted on bronchodilators in obstructive airways disease, the results of these clinical trials need to be interpreted with caution as older people are often under-represented and subjects with co-morbidities actively excluded from these trials.
- 1 January 2008
- Published by Springer Nature in Drugs & Aging
- Vol. 25 (5) , 415-443
Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People
Asthma and chronic obstructive pulmonary disease (COPD) are common disorders that are associated with increasing morbidity and mortality in older people. Bronchodilators are used widely in patients with these conditions, but even when used in inhaled form can have systemic as well as local effects. Older people experience more adverse drug effects because of pharmacodynamic and pharmacokinetic changes and particularly drug-drug and drug-disease interactions. Cardiovascular disease is common in older people and β-adrenoceptor agonists (β-agonists) have inotropic and chronotropic effects that can increase arrhythmias and cardiomyopathy. They can also worsen or induce myocardial ischaemia and cause electrolyte disturbances that contribute to arrhythmias. Tremor is a well known distressing adverse effect of β-agonist administration. Long-term β-agonist use can be associated with tolerance, poor disease control, sudden life-threatening exacerbations and asthma-related deaths. Functional β2-adrenoceptors are present in osteoblasts, and chronic use of β-agonists has been implicated in osteoporosis. Inhaled anticholinergics are usually well tolerated but may cause dry mouth, which can be troublesome in older people. Pupillary dilatation, blurred vision and acute glaucoma can occur from escape of droplets from loosely fitting nebulizer masks. Although ECG changes have not been seen in randomized controlled trials of long-acting inhaled anticholinergics, supraventricular tachycardias have been observed in a 5-year randomized controlled trial of ipratropium bromide. Paradoxical bronchoconstriction can occur with inhaled anticholinergics as well as with β-agonists, but tolerance has not been reported with anticholinergics. Anticholinergic drugs also cause central effects, most notably impairment of cognitive function, and these effects have been noted with inhaled agents. Use of theophylline is limited by its adverse effects, which range from commonly occurring gastrointestinal symptoms to palpitations, arrhythmias and reports of myocardial infarction. Seizures have been reported, but are rare. Theophylline is metabolized primarily by the liver, and commonly interacts with other medications. Its concentration in plasma should be monitored closely, especially in older people. Although many clinical trials have been conducted on bronchodilators in obstructive airways disease, the results of these clinical trials need to be interpreted with caution as older people are often under-represented and subjects with co-morbidities actively excluded from these trials.
- Open Access
- 1 November 2005
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 34 (6) , 603-608
Enzymes of drug metabolism during delirium
Background: delirium is common in ill medical patients. Several drugs and polypharmacy are recognised risk factors, yet little is known about drug metabolism in people with delirium. Objective: the aim of this study was to investigate the activities of plasma esterases (drug metabolising enzymes) in delirium. Design: this was a prospective study of delirium present at time of hospital admission (community acquired) or developing later (hospital acquired) in patients admitted as a medical emergency and aged 75 years or over. Methods: following informed consent or assent cognitive screening was completed on all patients on admission and every 48 hours subsequently. Delirium was diagnosed by Confusion Assessment Method and DSM IV criteria. Blood samples were taken on admission and at onset of delirium if this was later. Four plasma esterase assays were performed spectrophotometrically: acetylcholinesterase, aspirin esterase, benzoylcholinesterase, butyrylcholinesterase. Results: 283 patients (71% of eligible) were recruited, with mean age 82.4 years and 59% female. 27% had community acquired delirium, 10% developed hospital acquired delirium, 63% never developed delirium. On admission the mean activities of all four esterase assays were statistically significantly lower in delirious than non delirious patients. There were no significant differences on admission in any plasma esterase activity between patients with hospital and community acquired delirium. In-hospital mortality was associated with low plasma esterase activities on admission. Conclusion: plasma esterase activities are suppressed during delirium. These data reinforce the need for extreme caution with drugs in this vulnerable population.
- 1 November 2005
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 34 (6) , 603-608
Open AccessEnzymes of drug metabolism during delirium
Background: delirium is common in ill medical patients. Several drugs and polypharmacy are recognised risk factors, yet little is known about drug metabolism in people with delirium. Objective: the aim of this study was to investigate the activities of plasma esterases (drug metabolising enzymes) in delirium. Design: this was a prospective study of delirium present at time of hospital admission (community acquired) or developing later (hospital acquired) in patients admitted as a medical emergency and aged 75 years or over. Methods: following informed consent or assent cognitive screening was completed on all patients on admission and every 48 hours subsequently. Delirium was diagnosed by Confusion Assessment Method and DSM IV criteria. Blood samples were taken on admission and at onset of delirium if this was later. Four plasma esterase assays were performed spectrophotometrically: acetylcholinesterase, aspirin esterase, benzoylcholinesterase, butyrylcholinesterase. Results: 283 patients (71% of eligible) were recruited, with mean age 82.4 years and 59% female. 27% had community acquired delirium, 10% developed hospital acquired delirium, 63% never developed delirium. On admission the mean activities of all four esterase assays were statistically significantly lower in delirious than non delirious patients. There were no significant differences on admission in any plasma esterase activity between patients with hospital and community acquired delirium. In-hospital mortality was associated with low plasma esterase activities on admission. Conclusion: plasma esterase activities are suppressed during delirium. These data reinforce the need for extreme caution with drugs in this vulnerable population.
- Open Access
- 11 January 2005
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 34 (2) , 196-197
Reply
M. S. O’Mahony, S. F. Ho; Reply, Age and Ageing, Volume 34, Issue 2, 1 March 2005, Pages 196–197, https://doi.org/10.1093/ageing/afi022
- 11 January 2005
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 34 (2) , 196-197
Open AccessReply
M. S. O’Mahony, S. F. Ho; Reply, Age and Ageing, Volume 34, Issue 2, 1 March 2005, Pages 196–197, https://doi.org/10.1093/ageing/afi022
- 1 January 2005
- Published by Springer Nature in Drugs & Aging
- Vol. 22 (12) , 1029-1059
Overcoming Gaps in the Management of Asthma in Older Patients
Asthma is under-recognised and undertreated in older populations. This is not surprising, given that one-third of older people experience significant breathlessness. The differential diagnosis commonly includes asthma, chronic obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration and infections. Because symptoms and signs of several cardiorespiratory diseases are nonspecific in older people and diseases commonly co-exist, investigations are important. A simple strategy for the investigation of breathlessness in older people should include a full blood count, chest radiograph, ECG, peak flow diary and/or spirometry with reversibility as a minimum. If there are major abnormalities on the ECG, an echocardiogram should also be performed. Diurnal variability in peak flow readings ≥20% or ≥15% reversibility in forced expiratory volume in 1 second, spontaneously or with treatment, support a diagnosis of asthma. Distinguishing asthma from COPD is important to allow appropriate management of disease based on aetiology, accurate prediction of treatment response, correct prognosis and appropriate management of the chest condition and co-morbidities. The two conditions are usually readily differentiated by clinical features, particularly age at onset, variability of symptoms and nocturnal symptoms in asthma, supported by the results of reversibility testing. Full lung function tests may not necessarily help in differentiating the two entities, although gas transfer factor is characteristically reduced in COPD and usually normal or high in asthma. Methacholine challenge tests previously mainly used in research are now also used widely and safely to confirm asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker of airways inflammation is increasing as a noninvasive tool in the diagnosis and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the mainstay of treatment of asthma. Even in mild disease in older adults, regular preventive treatment should be considered, given the poor perception of bronchoconstriction by older asthmatic patients. If symptoms persist despite ICS, addition of long-acting β2-adrenoceptor agonists (LABA) should be considered. Addition of LABA to ICS improves asthma control and allows reduction in ICS dose. However, older people have been grossly under-represented in trials of LABA, many trials having excluded those ≥65 years of age. On meta-analysis, β2-adrenoceptor agonists (both short acting and long acting) are associated with increased cardiovascular mortality and morbidity in asthma and COPD. While the evidence for excess cardiovascular mortality is stronger for short-acting β2-adrenoceptor agonists, it would be prudent to exercise particular care in using β2-adrenoceptor agonists (long acting and short acting) in those at risk of adverse cardiovascular outcomes, including older people. Regular review of cardiovascular status (and monitoring of serum potassium concentration) in patients taking β2-adrenoceptor agonists is crucial. The response to LABA should be carefully monitored and alternative ‘add-on’ therapy such as leukotriene receptor antagonists (LRA) should be considered. LRA have fewer adverse effects and in individual cases may be more effective and appropriate than LABA. Long-term trials evaluating β2-adrenoceptor agonists and other bronchodilator strategies are needed particularly in the elderly and in patients with cardiovascular co-morbidities. There is no evidence that addition of anticholinergics improves control of asthma further, although the role of long-acting anticholinergics in the prevention of disease progression is currently being researched. Older patients need to be taught good inhaler technique to improve delivery of medications to lungs, minimise adverse effects and reduce the need for oral corticosteroids. Nurse-led education programmes that include a written asthma self-management plan have the potential to improve outcomes.
- 1 January 2005
- Published by Springer Nature in Drugs & Aging
- Vol. 22 (12) , 1029-1059
Overcoming Gaps in the Management of Asthma in Older Patients
Asthma is under-recognised and undertreated in older populations. This is not surprising, given that one-third of older people experience significant breathlessness. The differential diagnosis commonly includes asthma, chronic obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration and infections. Because symptoms and signs of several cardiorespiratory diseases are nonspecific in older people and diseases commonly co-exist, investigations are important. A simple strategy for the investigation of breathlessness in older people should include a full blood count, chest radiograph, ECG, peak flow diary and/or spirometry with reversibility as a minimum. If there are major abnormalities on the ECG, an echocardiogram should also be performed. Diurnal variability in peak flow readings ≥20% or ≥15% reversibility in forced expiratory volume in 1 second, spontaneously or with treatment, support a diagnosis of asthma. Distinguishing asthma from COPD is important to allow appropriate management of disease based on aetiology, accurate prediction of treatment response, correct prognosis and appropriate management of the chest condition and co-morbidities. The two conditions are usually readily differentiated by clinical features, particularly age at onset, variability of symptoms and nocturnal symptoms in asthma, supported by the results of reversibility testing. Full lung function tests may not necessarily help in differentiating the two entities, although gas transfer factor is characteristically reduced in COPD and usually normal or high in asthma. Methacholine challenge tests previously mainly used in research are now also used widely and safely to confirm asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker of airways inflammation is increasing as a noninvasive tool in the diagnosis and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the mainstay of treatment of asthma. Even in mild disease in older adults, regular preventive treatment should be considered, given the poor perception of bronchoconstriction by older asthmatic patients. If symptoms persist despite ICS, addition of long-acting β2-adrenoceptor agonists (LABA) should be considered. Addition of LABA to ICS improves asthma control and allows reduction in ICS dose. However, older people have been grossly under-represented in trials of LABA, many trials having excluded those ≥65 years of age. On meta-analysis, β2-adrenoceptor agonists (both short acting and long acting) are associated with increased cardiovascular mortality and morbidity in asthma and COPD. While the evidence for excess cardiovascular mortality is stronger for short-acting β2-adrenoceptor agonists, it would be prudent to exercise particular care in using β2-adrenoceptor agonists (long acting and short acting) in those at risk of adverse cardiovascular outcomes, including older people. Regular review of cardiovascular status (and monitoring of serum potassium concentration) in patients taking β2-adrenoceptor agonists is crucial. The response to LABA should be carefully monitored and alternative ‘add-on’ therapy such as leukotriene receptor antagonists (LRA) should be considered. LRA have fewer adverse effects and in individual cases may be more effective and appropriate than LABA. Long-term trials evaluating β2-adrenoceptor agonists and other bronchodilator strategies are needed particularly in the elderly and in patients with cardiovascular co-morbidities. There is no evidence that addition of anticholinergics improves control of asthma further, although the role of long-acting anticholinergics in the prevention of disease progression is currently being researched. Older patients need to be taught good inhaler technique to improve delivery of medications to lungs, minimise adverse effects and reduce the need for oral corticosteroids. Nurse-led education programmes that include a written asthma self-management plan have the potential to improve outcomes.
- Open Access
- 22 July 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (5) , 488-492
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community - a need for screening?
Background: heart failure and stroke are major causes of morbidity and mortality in older people. Angiotensin converting enzyme inhibitors improve symptoms and survival in left ventricular systolic dysfunction. Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative. Objectives: to determine the prevalence of left ventricular systolic dysfunction, health services utilisation and prescribing of diuretics and angiotensin converting enzyme inhibitors in left ventricular systolic dysfunction, and the prevalence of atrial fibrillation and anti-platelet/thrombotic therapy in atrial fibrillation in older people in the community. Methods: 500 subjects were drawn by two-stage random sampling from 5,002 subjects aged 70 years and over living at home. Subjects were screened for atrial fibrillation and left ventricular systolic dysfunction using electrocardiography and echocardiography. Results: the population prevalence amongst older people of left ventricular systolic dysfunction was 9.8% and of atrial fibrillation 7.8%. More than two-thirds of those with left ventricular systolic dysfunction were not on angiotensin converting enzyme inhibitors. Of those in atrial fibrillation, 35% were taking aspirin, 24% were taking warfarin and 41% were on neither aspirin nor warfarin. Nearly 90% of older people in the community have had contact with their general practitioner over the past year, and over half of those with left ventricular systolic dysfunction have had contact with hospital-based services over the past 2 years. Conclusions: left ventricular systolic dysfunction is under-treated in older people in the community. Despite the high level of contact with hospital and community-based services, the majority of those with systolic left ventricular dysfunction are not on angiotensin converting enzyme inhibitors and a significant proportion of those in atrial fibrillation are not on any treatment for stroke prevention.
- 22 July 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (5) , 488-492
Open AccessLeft ventricular systolic dysfunction and atrial fibrillation in older people in the community - a need for screening?
Background: heart failure and stroke are major causes of morbidity and mortality in older people. Angiotensin converting enzyme inhibitors improve symptoms and survival in left ventricular systolic dysfunction. Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative. Objectives: to determine the prevalence of left ventricular systolic dysfunction, health services utilisation and prescribing of diuretics and angiotensin converting enzyme inhibitors in left ventricular systolic dysfunction, and the prevalence of atrial fibrillation and anti-platelet/thrombotic therapy in atrial fibrillation in older people in the community. Methods: 500 subjects were drawn by two-stage random sampling from 5,002 subjects aged 70 years and over living at home. Subjects were screened for atrial fibrillation and left ventricular systolic dysfunction using electrocardiography and echocardiography. Results: the population prevalence amongst older people of left ventricular systolic dysfunction was 9.8% and of atrial fibrillation 7.8%. More than two-thirds of those with left ventricular systolic dysfunction were not on angiotensin converting enzyme inhibitors. Of those in atrial fibrillation, 35% were taking aspirin, 24% were taking warfarin and 41% were on neither aspirin nor warfarin. Nearly 90% of older people in the community have had contact with their general practitioner over the past year, and over half of those with left ventricular systolic dysfunction have had contact with hospital-based services over the past 2 years. Conclusions: left ventricular systolic dysfunction is under-treated in older people in the community. Despite the high level of contact with hospital and community-based services, the majority of those with systolic left ventricular dysfunction are not on angiotensin converting enzyme inhibitors and a significant proportion of those in atrial fibrillation are not on any treatment for stroke prevention.
- Open Access
- 22 July 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (5) , 510-511
Lesson of the week: perils of pessaries
Vaginal pessaries are widely considered to be a safe alternative to surgery in older women. We report a case of near fatal septicaemia in a 75-year-old woman associated with a shelf pessary, the presence of which was identified during an exploratory laparotomy. This case highlights the importance of the gynaecological history and examination when assessing older women with septicaemia of unknown source.
- 22 July 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (5) , 510-511
Open AccessLesson of the week: perils of pessaries
Vaginal pessaries are widely considered to be a safe alternative to surgery in older women. We report a case of near fatal septicaemia in a 75-year-old woman associated with a shelf pessary, the presence of which was identified during an exploratory laparotomy. This case highlights the importance of the gynaecological history and examination when assessing older women with septicaemia of unknown source.
- Open Access
- 19 May 2004
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 97 (6) , 377-378
Pancreatic insufficiency and weight loss in older patients
Pancreatic insufficiency and weight loss in older patients Sir, Weight loss is an important independent predictor of increased mortality in the older population. 1 We report three cases of weight loss secondary to pancreatic insufficiency in elderly patients with no previous pancreatic disease. An 80-year-old widower, presented with a six month history of lethargy, anorexia and weight loss of 6 kg. He was suffering a prolonged bereavement reaction associated with recent alcohol excess following the death of his wife. He weighed 44.5 kg, haemoglobin was 13.5 g/dl. The patient's mood and appetite improved on antidepressant therapy and alcohol withdrawal, but he failed to gain weight, and reported episodes of intermittent diarrhoea. Barium enema and coeliac screen were unremarkable. Pancreatic insufficiency was diagnosed with a positive pancreolauryl test of 14.4% (normal range >30%). The patient's diarrhoea stopped and he gained 14 kg in 10 months following pancreatic enzyme supplementation. An 80-year-old man presented with vomiting several hours after eating and weight loss of approximately 6 kg in one month. Haemoglobin was 12.4 g/dl. Endoscopy, upper gastrointestinal tract biopsy, barium enema, abdominal ultrasound and coeliac screen were unremarkable. Pancreolauryl test was positive at 12.2% and CT scan showed pancreatic atrophy, but no calcification. His symptoms resolved, and he gained 8 kg in one month following pancreatic enzyme supplementation. A 78-year-old woman was admitted with a 5-day history of diarrhoea following antibiotics for a chest infection. She also reported weight loss and malaise over a 1 month period. She weighed 39.2 kg, haemoglobin was 10.0 g/dl, and serum ferritin 40 mg/l (15-300 mg/l). Barium enema, upper endoscopy, coeliac screen and abdominal CT scan were normal. Pancreolauryl test was positive at 9.2%,
- 19 May 2004
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 97 (6) , 377-378
Open AccessPancreatic insufficiency and weight loss in older patients
Pancreatic insufficiency and weight loss in older patients Sir, Weight loss is an important independent predictor of increased mortality in the older population. 1 We report three cases of weight loss secondary to pancreatic insufficiency in elderly patients with no previous pancreatic disease. An 80-year-old widower, presented with a six month history of lethargy, anorexia and weight loss of 6 kg. He was suffering a prolonged bereavement reaction associated with recent alcohol excess following the death of his wife. He weighed 44.5 kg, haemoglobin was 13.5 g/dl. The patient's mood and appetite improved on antidepressant therapy and alcohol withdrawal, but he failed to gain weight, and reported episodes of intermittent diarrhoea. Barium enema and coeliac screen were unremarkable. Pancreatic insufficiency was diagnosed with a positive pancreolauryl test of 14.4% (normal range >30%). The patient's diarrhoea stopped and he gained 14 kg in 10 months following pancreatic enzyme supplementation. An 80-year-old man presented with vomiting several hours after eating and weight loss of approximately 6 kg in one month. Haemoglobin was 12.4 g/dl. Endoscopy, upper gastrointestinal tract biopsy, barium enema, abdominal ultrasound and coeliac screen were unremarkable. Pancreolauryl test was positive at 12.2% and CT scan showed pancreatic atrophy, but no calcification. His symptoms resolved, and he gained 8 kg in one month following pancreatic enzyme supplementation. A 78-year-old woman was admitted with a 5-day history of diarrhoea following antibiotics for a chest infection. She also reported weight loss and malaise over a 1 month period. She weighed 39.2 kg, haemoglobin was 10.0 g/dl, and serum ferritin 40 mg/l (15-300 mg/l). Barium enema, upper endoscopy, coeliac screen and abdominal CT scan were normal. Pancreolauryl test was positive at 9.2%,
- Open Access
- 1 March 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (2) , 185-188
Inhaler technique in older people in the community
Background: good inhaler technique and medication concordance is important for symptom and disease control in chronic airways disease. Objectives: establish the prevalence of inhaler use; the main inhaler devices used by older people at home; their ability to use the inhalers they have been prescribed; and the relationship between perceived ease of use and actual performance. Design: cross-sectional population based study. Subjects: subjects aged 70 years and over living at home. Methods: 500 subjects were randomly selected from 5,002 subjects aged 70 years and over living at home. Inhalers used over the previous 24 hours were identified by a nurse on home visit. Those with cognitive impairment were excluded. Inhaler system was assessed and graded by a doctor as acceptable (perfect or minor errors) or unacceptable (major errors), using previously published criteria. Perceived ease of use of the device was rated as easy, moderate or difficult. Results: 423 subjects participated in the study. The population prevalence of inhaler use was 15.8% (12.0, 19.7). Of the 91 inhaler devices used, 39 (42.8%) were metered dose inhalers, 34 (37.4%) were metered dose inhalers with large volume spacers, and 18 (19.8%) were breath-actuated devices. Thirty-two subjects (82.1%) using metered dose inhalers had an acceptable technique compared with 33 (97.1%) of those using metered dose inhalers with large volume spacers and 13 (72.2%) of those using breath-actuated devices (P < 0.05). Up to three quarters of inhalers were considered easy to use but 12% of subjects who rated their inhaler device as being easy to use made major errors. Conclusion: metered dose inhaler was the most frequently prescribed inhaler and was used correctly by most subjects especially in combination with large volume spacers. Major errors were more common with breath-actuated devices. Inhaler technique should be checked as patients’ perception of their inhaler skills correlates poorly with actual performance.
- 1 March 2004
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 33 (2) , 185-188
Open AccessInhaler technique in older people in the community
Background: good inhaler technique and medication concordance is important for symptom and disease control in chronic airways disease. Objectives: establish the prevalence of inhaler use; the main inhaler devices used by older people at home; their ability to use the inhalers they have been prescribed; and the relationship between perceived ease of use and actual performance. Design: cross-sectional population based study. Subjects: subjects aged 70 years and over living at home. Methods: 500 subjects were randomly selected from 5,002 subjects aged 70 years and over living at home. Inhalers used over the previous 24 hours were identified by a nurse on home visit. Those with cognitive impairment were excluded. Inhaler system was assessed and graded by a doctor as acceptable (perfect or minor errors) or unacceptable (major errors), using previously published criteria. Perceived ease of use of the device was rated as easy, moderate or difficult. Results: 423 subjects participated in the study. The population prevalence of inhaler use was 15.8% (12.0, 19.7). Of the 91 inhaler devices used, 39 (42.8%) were metered dose inhalers, 34 (37.4%) were metered dose inhalers with large volume spacers, and 18 (19.8%) were breath-actuated devices. Thirty-two subjects (82.1%) using metered dose inhalers had an acceptable technique compared with 33 (97.1%) of those using metered dose inhalers with large volume spacers and 13 (72.2%) of those using breath-actuated devices (P < 0.05). Up to three quarters of inhalers were considered easy to use but 12% of subjects who rated their inhaler device as being easy to use made major errors. Conclusion: metered dose inhaler was the most frequently prescribed inhaler and was used correctly by most subjects especially in combination with large volume spacers. Major errors were more common with breath-actuated devices. Inhaler technique should be checked as patients’ perception of their inhaler skills correlates poorly with actual performance.
- Open Access
- 1 September 2003
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 32 (5) , 519-524
Diastolic heart failure in older people
Objectives: to determine the prevalence of diastolic heart failure in older people in the community, identify associated risk factors and measure its impact on function and quality of life. Design: cross-sectional population-based study. Methods: a two-stage random sample of 500 subjects was drawn from 5,002 subjects aged 70 years and over living at home. Diastolic heart failure was diagnosed by a panel of three physicians, based on clinical assessment and echocardiographic indicators of diastolic dysfunction. Main outcome measures: prevalence of diastolic heart failure and its effect on function and quality of life as measured by Nottingham Extended Activities of Daily Living, Hospital Anxiety and Depression and SF-36 questionnaires. Results: the prevalence of diastolic heart failure was 5.54% (95% CI = 3.71, 7.87) and was higher in women (8.32%) than in men (1.25%), P = 0.008. On multivariate analysis of variance, diastolic heart failure was associated with female gender and history of ischaemic heart disease. Subjects with diastolic heart failure had signiWcantly poorer functional status and physical health than those without heart failure. Conclusions: Diastolic heart failure is relatively common in older people and is associated with adverse affects in older people’s lives.
- 1 September 2003
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 32 (5) , 519-524
Open AccessDiastolic heart failure in older people
Objectives: to determine the prevalence of diastolic heart failure in older people in the community, identify associated risk factors and measure its impact on function and quality of life. Design: cross-sectional population-based study. Methods: a two-stage random sample of 500 subjects was drawn from 5,002 subjects aged 70 years and over living at home. Diastolic heart failure was diagnosed by a panel of three physicians, based on clinical assessment and echocardiographic indicators of diastolic dysfunction. Main outcome measures: prevalence of diastolic heart failure and its effect on function and quality of life as measured by Nottingham Extended Activities of Daily Living, Hospital Anxiety and Depression and SF-36 questionnaires. Results: the prevalence of diastolic heart failure was 5.54% (95% CI = 3.71, 7.87) and was higher in women (8.32%) than in men (1.25%), P = 0.008. On multivariate analysis of variance, diastolic heart failure was associated with female gender and history of ischaemic heart disease. Subjects with diastolic heart failure had signiWcantly poorer functional status and physical health than those without heart failure. Conclusions: Diastolic heart failure is relatively common in older people and is associated with adverse affects in older people’s lives.
- Open Access
- 1 January 2002
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 31 (1) , 23-28
beta-blockers in left ventricular systolic dysfunction--from evidence to practice
Five percent of all hospital medical admissions are patients with heart failure. The incidence is about one new case per 1000 of the general population per year, increasing to >10 per 1000 in those aged ⩾85 years. Although the evidence that β‐blockers reduce mortality by about 36% when added to angiotensin‐converting enzyme inhibitors is overwhelming, clinicians are still reluctant to use β‐blockers in heart failure, especially in older patients. Here, we examine the evidence for the use of β‐blockers in heart failure in older people and explore the practicalities of their use.
- 1 January 2002
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 31 (1) , 23-28
Open Accessbeta-blockers in left ventricular systolic dysfunction--from evidence to practice
Five percent of all hospital medical admissions are patients with heart failure. The incidence is about one new case per 1000 of the general population per year, increasing to >10 per 1000 in those aged ⩾85 years. Although the evidence that β‐blockers reduce mortality by about 36% when added to angiotensin‐converting enzyme inhibitors is overwhelming, clinicians are still reluctant to use β‐blockers in heart failure, especially in older patients. Here, we examine the evidence for the use of β‐blockers in heart failure in older people and explore the practicalities of their use.